Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Benzinga · 3d ago
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.